Harvard logo

Harvard Medical School

Industry Partner

At the Immunobiology Laboratories at Harvard Medical School and Massachusetts General Hospital
perform studies on the basic biology TNF superfamily receptors, with an emphasis on autoimmunity and cancer. TNFR2 identifies Treg cells with the highest potency; in human cancers TNFR2 is overexpressed in the tumor microenvironment and in autoimmunity it is under-expressed on Tregs.
Recent data suggests agonistic TNFR2 antibodies can be made (Science Signaling 2020). For potent TNF superfamily agonism or antagonism, the final surface structures must have either tight hexagonal networks (agonism) or larger hexagonal networks (antagonism). Humanized antibodies to TNFR2 have now been produced using these principle
with broad verification of these desired structural constructs.


Revolo Biotherapeutics

Industry Partner

We are a revolutionary biotherapeutics company with a mission to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission
without the need for chronic dosing and without suppressing the immune system. Our two platform drug candidates, ‘1805 and ‘1104, reset the immune system suppressing only a single administration.
They have demonstrated unique efficacy and safety in preclinical and human studies.


Sangamo Therapeutics

Industry Partner

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation.

Akron Biotech Logo.png

Akron Biotech

Innovation Partner 

Akron Biotech drives advanced therapy development and commercialization with high quality, industrial scale solutions. A regulatory compliant (ISO-certified) company, Akron’s strategic focus is manufacturing cGMP-compliant ancillary materials and providing services that enable the advancement of cell and gene therapies. These include cytokines and growth factors, human sera and purified proteins, cryopreservation solutions, plasmid DNA manufacturing and custom development services.


Adaptative Biotechnologies

Event Partner

Adaptive Biotechnologies is a pioneer in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive Therapeutics’ platform allows the discovery of potent, ultra-low frequency TCRs with differentiated therapeutic potential. This TruTCRTM engine combines Adaptive’s foundational immunosequencing platform with a multiplex approach to map TCRs to antigens at high specificity plus pairSEQTM to accurately pair TCR alpha/beta chains. Adaptive has discovered and is validating candidate TCRs with superior cytolytic activity in oncology.



Event Partner

As one of the leading companies in the immune cell therapy with Regulatory T (Treg) cells, TeraImmune is providing innovative Treg cell therapies for the patients with autoimmune diseases. Our proprietary technologies make it possible to consistently produce disease-specific Tregs that retain their suppressive function. TeraImmune is building a solid foundation for Treg cell therapy and aims to conduct a first-in-human study with a ‘FVIII-TCR Treg’ targeting the anti-FVIII antibody formation in severe Hemophilia A.